PT  - JOURNAL ARTICLE
AU  - Cloete, Jeané
AU  - Kruger, Annelet
AU  - Masha, Maureen
AU  - du Plessis, Nicolette M
AU  - Mawela, Dini
AU  - Tshukudu, Mphailele
AU  - Manyane, Tabea
AU  - Komane, Lekwetji
AU  - Venter, Marietjie
AU  - Jassat, Waasila
AU  - Goga, Ameena
AU  - Feucht, Ute
TI  - Rapid rise in paediatric COVID-19 hospitalisations during the early stages of the Omicron wave, Tshwane District, South Africa
AID  - 10.1101/2021.12.21.21268108
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.21.21268108
4099  - http://medrxiv.org/content/early/2021/12/21/2021.12.21.21268108.short
4100  - http://medrxiv.org/content/early/2021/12/21/2021.12.21.21268108.full
AB  - Background South Africa reported a notable increase in COVID-19 cases from mid-November 2021 onwards, starting in Tshwane District, linked to rapid community spread of the Omicron variant. This coincided with a rapid rise in paediatric COVID-19-associated hospitalisations.Methods We synthesized data from five sources to describe the impact of Omicron on clinical manifestations and outcomes of hospitalized children (≤19 years) with positive SARS-CoV-2 tests in Tshwane District from 31 October to 11 December 2021, including: 1) COVID-19 line lists; 2) collated SARS-CoV-2 testing data; 3) SARS-CoV-2 genomic sequencing data; 4) COVID-19 hospitalisation surveillance; and 5) clinical data of public sector paediatric (≤13 years) COVID-19 hospitalisations.Findings During the six-week period 6,287 paediatric (≤19 years) COVID-19 cases were recorded in Tshwane District, of these 462 (7.2%) were hospitalized in 42 hospitals (18% of overall admissions). The number of paediatric cases was higher than in the prior 3 waves, uncharacteristically preceding adult hospitalisations. Of the 75 viral specimens sequenced from the district, 99% were Omicron. Detailed clinical information obtained from 139 of 183 (76%) admitted children (≤13 years; including all public sector hospitalisations) indicated that young children (0-4 years) were most affected (62%). Symptoms included fever (47%), cough (40%), vomiting (24%), difficulty breathing (23%), diarrhoea (20%) and convulsions (20%). Length of hospital stay was short (mean 3.2 days), and in 44% COVID-19 was the primary diagnosis. Most children received standard ward care (92%), with 31 (25%) receiving oxygen therapy. Seven children (6%) were ventilated; four children died, all related to complex underlying co-pathologies. All children and majority of parents for whom data were available were unvaccinated.Interpretation Rapid increases in paediatric COVID-19 cases and hospitalisations mirror high community transmission of SARS-CoV-2 (Omicron variant) in Tshwane District, South Africa. Continued monitoring is needed to understand the long-term impact of the Omicron variant on children.Evidence before the study The announcement of the new Omicron (B.1.1.529) variant of the SARS-CoV-2 virus was made on 24 November 2021. Clinical characteristics, and disease profiles of children with COVID-19 before the arrival of Omicron have been described in the literature.Added value of the study This study describes the rapid rise in paediatric COVID-19-associated hospitalisations in Tshwane District in the Gauteng Province of South Africa – one of the first known epicentres of the new Omicron variant of the SARS-CoV-2 virus. The clinical picture as well as the steep increase in paediatric positivity rates and hospitalizations are described in detail from the perspective of a large South African health district, providing a broad overview on how the Omicron variant affects the paediatric population.Implication of all available evidence This study describes the clinical picture and outcomes in children in the current wave of SARS-CoV-2 Omicron variant infections by incorporating data from 42 hospitals at all levels of care in a large district within the South African health system. This provides novel paediatric data to assist global preparation for the impact of the Omicron variant in the paediatric setting.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe South African Medical Research Council is acknowledged for funding of the SA COVID kids study and staff time (AG). The Zoonotic arbo and Respiratory virus Research Programme is funded through the African Network for improved Diagnostics, Epidemiology and Management of Common Infectious Agents ANDEMIA, COVID-19 fund, G7 global Health fund. NGS-SA is funded by the Department of Science & Innovation (DSI) and the South African Medical Research Council (SAMRC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical and institutional approvals were obtained by the following: The Tshwane COVID-19 research study received permission from Ethics Committees of both Health Sciences Faculties in Tshwane (University of Pretoria Reference Number 822/2020; Sefako Makgatho Health Sciences University Reference Number SMUREC/M/54/2021:IR), together with the Tshwane District Research Committee. Additionally, the three large public sector hospitals are part of the SA COVID KIDS study (Reference Number EC048-11/2020; South African Medical Research Council). Ethics approval was also obtained for sequencing of COVID-19 samples through the University of Pretoria Ethics Committee (Reference Number 101/2017).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors